- Home
- CUE vs LRFC Comparison
CUE vs LRFC Comparison
Compare CUE & LRFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- LRFC
- Stock Information
- Founded
- CUE 2014
- LRFC 2013
- Country
- CUE United States
- LRFC United States
- Employees
- CUE N/A
- LRFC N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- LRFC Finance: Consumer Services
- Sector
- CUE Health Care
- LRFC Finance
- Exchange
- CUE Nasdaq
- LRFC Nasdaq
- Market Cap
- CUE 77.3M
- LRFC 68.2M
- IPO Year
- CUE 2018
- LRFC 2013
- Fundamental
- Price
- CUE $1.31
- LRFC $23.92
- Analyst Decision
- CUE Strong Buy
- LRFC
- Analyst Count
- CUE 5
- LRFC 0
- Target Price
- CUE $5.00
- LRFC N/A
- AVG Volume (30 Days)
- CUE 406.9K
- LRFC 6.4K
- Earning Date
- CUE 03-10-2025
- LRFC 03-12-2025
- Dividend Yield
- CUE N/A
- LRFC 5.60%
- EPS Growth
- CUE N/A
- LRFC N/A
- EPS
- CUE N/A
- LRFC N/A
- Revenue
- CUE $9,532,000.00
- LRFC $19,936,000.00
- Revenue This Year
- CUE $73.11
- LRFC $3.63
- Revenue Next Year
- CUE $11.02
- LRFC N/A
- P/E Ratio
- CUE N/A
- LRFC N/A
- Revenue Growth
- CUE 149.53
- LRFC N/A
- 52 Week Low
- CUE $0.45
- LRFC $20.65
- 52 Week High
- CUE $2.93
- LRFC $26.00
- Technical
- Relative Strength Index (RSI)
- CUE 52.47
- LRFC 38.64
- Support Level
- CUE $1.21
- LRFC $23.78
- Resistance Level
- CUE $1.75
- LRFC $24.80
- Average True Range (ATR)
- CUE 0.18
- LRFC 0.51
- MACD
- CUE 0.00
- LRFC -0.07
- Stochastic Oscillator
- CUE 45.00
- LRFC 20.59
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
About LRFC Logan Ridge Finance Corporation
Logan Ridge Finance Corp an externally managed non-diversified closed-end management investment company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company offers customized financing to business owners, management teams, and financial sponsors for change of ownership transactions, recapitalizations, strategic acquisitions, business expansion, and other growth initiatives.